Minta, Karolina
Brinkmalm, Gunnar
Al Nimer, Faiez
Thelin, Eric P.
Piehl, Fredrik
Tullberg, Mats
Jeppsson, Anna
Portelius, Erik
Zetterberg, Henrik
Blennow, Kaj
Andreasson, Ulf
Funding for this research was provided by:
Stiftelsen för Gamla Tjänarinnor
Herbert och Karin Jacobssons Stiftelse
Gun och Bertil Stohnes Stiftelse
Hjärnfonden (FO2019-0006, FO2017-0243)
Svenska Sällskapet för Medicinsk Forskning
Swedish Research Council (2018-02532, 2017-00915)
European Research Council (681712)
Swedish State Support for Clinical Research (ALFGBG-720931)
UK Dementia Research Institute at UCL
Alzheimer's Drug Discovery Foundation (RDAPB-201809-2016615)
Swedish Alzheimer Foundation (AF-742881)
Swedish state under the agreement between the Swedish government and the County Councils
ALF-agreement (ALFGBG-715986)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
Gothenburg University Library
Article History
Received: 2 May 2020
Accepted: 7 October 2020
First Online: 22 October 2020
Competing interests
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KM, GB, EP, FP, EPT, AJ, MT, FN and UA declare that they have no competing interests.